Daniel O'Day, William Anderson

Daniel O'Day will leave his post as CEO and corporate executive committee member of Roche Pharmaceuticals at the end of December to become CEO and board chairman of Gilead Sciences, effective March 1, 2019.

In the interim period, he will provide support to Roche to ensure a smooth transition to his successor, William Anderson, who will become CEO of Roche Pharmaceuticals effective Jan. 1, 2019. Anderson currently serves as CEO of Roche-owned Genentech, which he joined in 2006. In previous roles, he led Genentech's immunology business unit, headed oncology sales and marketing, and led global product strategy.